Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  6/22/2011
Montefiore Medical Center
mi
from
Bronx, NY
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 6/22/2011
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  6/22/2011
Montefiore Medical Center
mi
from
Bronx, NY
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 6/22/2011
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
A Phase II Study of Bone Marker Assessment of Multiple Myeloma Patients Treated With AminoBisphosphonates
Status: Enrolling
Updated:  7/19/2011
Massachusetts General Hospital
mi
from
Boston, MA
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
A Phase II Study of Bone Marker Assessment of Multiple Myeloma Patients Treated With AminoBisphosphonates
Status: Enrolling
Updated: 7/19/2011
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Omega 3 Supplementation for the Prevention of Disease Progression in Early Stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies
Status: Enrolling
Updated:  7/29/2011
Edwards Comprehensive Cancer Center
mi
from
Huntington, WV
Omega 3 Supplementation for the Prevention of Disease Progression in Early Stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies
Status: Enrolling
Updated: 7/29/2011
Edwards Comprehensive Cancer Center
mi
from
Huntington, WV
Click here to add this to my saved trials
Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
Phase 1 Study of Cladribine Based Induction Therapy (CLAG) With ATRA (All-Trans Retinoic Acid) and Midostaurin in Relapsed/Refractory AML
Status: Enrolling
Updated:  9/19/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
Phase 1 Study of Cladribine Based Induction Therapy (CLAG) With ATRA (All-Trans Retinoic Acid) and Midostaurin in Relapsed/Refractory AML
Status: Enrolling
Updated: 9/19/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Endothelial Function, Arterial Stiffness and Components
Endothelial Function, Arterial Stiffness and Components of Metabolic Syndrome in Acute Lymphoblastic Leukemia (ALL) Survivors
Status: Enrolling
Updated:  9/22/2011
Johns Hopkins Hospital
mi
from
Baltimore, MD
Endothelial Function, Arterial Stiffness and Components
Endothelial Function, Arterial Stiffness and Components of Metabolic Syndrome in Acute Lymphoblastic Leukemia (ALL) Survivors
Status: Enrolling
Updated: 9/22/2011
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Status: Enrolling
Updated:  9/26/2011
Cornell University
mi
from
New York, NY
A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Status: Enrolling
Updated: 9/26/2011
Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Status: Enrolling
Updated:  9/26/2011
North Shore University Hospital
mi
from
New Hyde Park, NY
A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Status: Enrolling
Updated: 9/26/2011
North Shore University Hospital
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Status: Enrolling
Updated:  9/26/2011
Oregon Health Sciences University
mi
from
Portland, OR
A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Status: Enrolling
Updated: 9/26/2011
Oregon Health Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Status: Enrolling
Updated:  9/26/2011
Univ. of San Diego: Moores UCSD Cancer Center
mi
from
La Jolla, CA
A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Status: Enrolling
Updated: 9/26/2011
Univ. of San Diego: Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Status: Enrolling
Updated:  9/26/2011
Univ of Minnesota
mi
from
Minneapolis, MN
A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Status: Enrolling
Updated: 9/26/2011
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
Mobilization Kinetics of Plerixafor and G-CSF in Patients With NHL and MM Undergoing Autologous Peripheral Blood Progenitor Cell Collection
Status: Enrolling
Updated:  9/26/2011
Mount Sinai School of Medicine
mi
from
New York, NY
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
Mobilization Kinetics of Plerixafor and G-CSF in Patients With NHL and MM Undergoing Autologous Peripheral Blood Progenitor Cell Collection
Status: Enrolling
Updated: 9/26/2011
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Oral Clofarabine for Acute Myeloid Leukemia
Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia
Status: Enrolling
Updated:  10/6/2011
Washington University
mi
from
St. Louis, MO
Oral Clofarabine for Acute Myeloid Leukemia
Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia
Status: Enrolling
Updated: 10/6/2011
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
SHP2 as a Therapeutic Target For Myelodysplastic Syndrome: Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
Status: Enrolling
Updated:  10/19/2011
Northwestern University
mi
from
Chicago, IL
Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
SHP2 as a Therapeutic Target For Myelodysplastic Syndrome: Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
Status: Enrolling
Updated: 10/19/2011
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
SHP2 as a Therapeutic Target For Myelodysplastic Syndrome: Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
Status: Enrolling
Updated:  10/19/2011
Jesse Brown VHA Medical Center
mi
from
Chicago, IL
Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
SHP2 as a Therapeutic Target For Myelodysplastic Syndrome: Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
Status: Enrolling
Updated: 10/19/2011
Jesse Brown VHA Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Lenalidomide in HTLV-1 Adult T-Cell Leukemia
A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  10/27/2011
Columbia University Medical Center
mi
from
New York, NY
Lenalidomide in HTLV-1 Adult T-Cell Leukemia
A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 10/27/2011
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Metformin and Transient Hyperglycemia
Metformin as an Adjunctive Therapy For Transient Hyperglycemia in Patients With Acute Lymphoblastic Leukemia During Induction Chemotherapy
Status: Enrolling
Updated:  12/2/2011
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Metformin and Transient Hyperglycemia
Metformin as an Adjunctive Therapy For Transient Hyperglycemia in Patients With Acute Lymphoblastic Leukemia During Induction Chemotherapy
Status: Enrolling
Updated: 12/2/2011
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
A Trial of Rituximab Combined With Prednisone/Ifosfamide/Etoposide for Relapsed Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  1/13/2012
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
A Trial of Rituximab Combined With Prednisone/Ifosfamide/Etoposide for Relapsed Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 1/13/2012
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
A Trial of Rituximab Combined With Prednisone/Ifosfamide/Etoposide for Relapsed Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  1/13/2012
Emory University
mi
from
Atlanta, GA
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
A Trial of Rituximab Combined With Prednisone/Ifosfamide/Etoposide for Relapsed Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 1/13/2012
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
A Trial of Rituximab Combined With Prednisone/Ifosfamide/Etoposide for Relapsed Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  1/13/2012
Children's Mercy Hospital
mi
from
Kansas City, MO
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
A Trial of Rituximab Combined With Prednisone/Ifosfamide/Etoposide for Relapsed Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 1/13/2012
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Phase II Trial of CLAG-M in Relapsed ALL
Status: Enrolling
Updated:  1/19/2012
Westchester Medical Center/New York Medical College
mi
from
Valhalla, NY
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Phase II Trial of CLAG-M in Relapsed ALL
Status: Enrolling
Updated: 1/19/2012
Westchester Medical Center/New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated:  2/3/2012
Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program
mi
from
Boston, MA
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated: 2/3/2012
Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program
mi
from
Boston, MA
Click here to add this to my saved trials
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated:  2/3/2012
Massachusetts General Hospital
mi
from
Boston, MA
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated: 2/3/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated:  2/3/2012
Ohio State Univeristy Comprehensive Cancer Center
mi
from
Columbus, OH
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated: 2/3/2012
Ohio State Univeristy Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Status: Enrolling
Updated:  2/9/2012
Duke Univ Med Ctr
mi
from
Durham, NC
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Status: Enrolling
Updated: 2/9/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study of EB10 in Patients With Leukemia
An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/24/2012
ImClone Investigational Site
mi
from
Columbus, OH
Study of EB10 in Patients With Leukemia
An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/24/2012
ImClone Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of EB10 in Patients With Leukemia
An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/24/2012
ImClone Investigational Site
mi
from
Houston, TX
Study of EB10 in Patients With Leukemia
An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/24/2012
ImClone Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Infusion of Genetically Modified T Cells: A Pilot Study of Tracking and Toxicity
Status: Enrolling
Updated:  3/2/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Infusion of Genetically Modified T Cells: A Pilot Study of Tracking and Toxicity
Status: Enrolling
Updated: 3/2/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  3/6/2012
Rady Children's Hospital and Health Center
mi
from
San Diego, CA
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 3/6/2012
Rady Children's Hospital and Health Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  3/6/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 3/6/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Allo CART-19 Protocol
Pilot Study of Donor Lymphocyte Infusions Using Donor T Cells Engineered to Contain Anti-CD19 Attached To TCR And 4-1BB Signaling Domains in Patients With Relapsed CD19+ All After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  3/9/2012
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Allo CART-19 Protocol
Pilot Study of Donor Lymphocyte Infusions Using Donor T Cells Engineered to Contain Anti-CD19 Attached To TCR And 4-1BB Signaling Domains in Patients With Relapsed CD19+ All After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 3/9/2012
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy With ATRA and Arsenic Trioxide (STAR-1)
Status: Enrolling
Updated:  3/13/2012
Northwestern University
mi
from
Chicago, IL
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy With ATRA and Arsenic Trioxide (STAR-1)
Status: Enrolling
Updated: 3/13/2012
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy With ATRA and Arsenic Trioxide (STAR-1)
Status: Enrolling
Updated:  3/13/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy With ATRA and Arsenic Trioxide (STAR-1)
Status: Enrolling
Updated: 3/13/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated:  3/16/2012
University of California at Los Angeles
mi
from
Los Angeles, CA
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated: 3/16/2012
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated:  3/16/2012
University of Kansas Medical Center
mi
from
Kansas City, KA
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated: 3/16/2012
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Sutter East Bay Hospitals
mi
from
Berkley, CA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Sutter East Bay Hospitals
mi
from
Berkley, CA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Palm Springs Research Institute
mi
from
Hialeah, FL
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Palm Springs Research Institute
mi
from
Hialeah, FL
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
MCG Cancer Center
mi
from
Augusta, GA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
MCG Cancer Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Kansas University Medical Center
mi
from
Kansas City, KA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Kansas University Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
University of Kentucky Markey Cancer Center Clinical Research Organization
mi
from
Lexington, KY
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
University of Kentucky Markey Cancer Center Clinical Research Organization
mi
from
Lexington, KY
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Montefiore Medical Center
mi
from
Bronx, NY
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Mid Dakota Clinical P.C. - Cancer Treatment and Research Center
mi
from
Bismarck, ND
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Mid Dakota Clinical P.C. - Cancer Treatment and Research Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Gabrail Cancer Center
mi
from
Canton, OH
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Pharma Resource
mi
from
East Providence, RI
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Pharma Resource
mi
from
East Providence, RI
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Virginia Commonwealth University
mi
from
Richmond, VA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Phase I Clinical Trial of Bendamustine, Lenalidomide and Rituximab in B-Cell Lymphoid Malignancies
Status: Enrolling
Updated:  4/3/2012
Georgetown University Hospital Lombardi Cancer Center
mi
from
Washington,
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Phase I Clinical Trial of Bendamustine, Lenalidomide and Rituximab in B-Cell Lymphoid Malignancies
Status: Enrolling
Updated: 4/3/2012
Georgetown University Hospital Lombardi Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation
T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation
Status: Enrolling
Updated:  4/10/2012
Texas Children's Hospital
mi
from
Houston, TX
Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation
T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation
Status: Enrolling
Updated: 4/10/2012
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials